Pharmaco-transcriptomicsUp/down regulation of genes due to the metabolism of pharmaceutical compounds

Pharmaco-genomics Pharmaco-metabolomics Pharmaco-transcriptomics Pharmaco-proteomics Search

Displaying entries 28401 - 28425 of 102031 in total

Drug	Drug Groups	Gene	Gene ID	Change	Interaction	Chromosome	References
							Clear
Cytarabine	Approved Investigational	EIF4H	7458	downregulated	Cytarabine results in decreased expression of EIF4H mRNA	7q11.23	A21886
Cytarabine	Approved Investigational	ENO3	2027	downregulated	Cytarabine results in decreased expression of ENO3 mRNA	17p13.2	A21886
Cytarabine	Approved Investigational	ENTPD1	953	upregulated	Cytarabine results in increased expression of ENTPD1 mRNA	10q24.1	A20985
Cytarabine	Approved Investigational	EXOG	9941	downregulated	Cytarabine results in decreased expression of EXOG mRNA	3p22.2	A21886
Cytarabine	Approved Investigational	EXT2	2132	downregulated	Cytarabine results in decreased expression of EXT2 mRNA	11p11.2	A21886
Cytarabine	Approved Investigational	EZR	7430	downregulated	Cytarabine results in decreased expression of EZR mRNA	6q25.3	A21886
Cytarabine	Approved Investigational	FABP7	2173	upregulated	Cytarabine results in increased expression of FABP7 mRNA	6q22.31	A21886
Cytarabine	Approved Investigational	FAM111A	63901	upregulated	Cytarabine results in increased expression of FAM111A mRNA	11q12.1	A20985
Cytarabine	Approved Investigational	FAM129B	64855	downregulated	Cytarabine results in decreased expression of FAM129B mRNA	9q34.11	A21886
Cytarabine	Approved Investigational	FAM46A	55603	downregulated	Cytarabine results in decreased expression of FAM46A mRNA	6q14.1	A21886
Cytarabine	Approved Investigational	FAM46C	54855	downregulated	Cytarabine results in decreased expression of FAM46C mRNA	1p12	A21886
Cytarabine	Approved Investigational	FBLN1	2192	downregulated	Cytarabine results in decreased expression of FBLN1 mRNA	22q13.31	A21886
Cytarabine	Approved Investigational	FBXO2	26232	downregulated	Cytarabine results in decreased expression of FBXO2 mRNA	1p36.22	A21886
Cytarabine	Approved Investigational	FCGR2A	2212	upregulated	Cytarabine results in increased expression of FCGR2A mRNA	1q23.3	A20985
Cytarabine	Approved Investigational	FCGR2C	9103	upregulated	Cytarabine results in increased expression of FCGR2C mRNA	1q23.3	A20985
Cytarabine	Approved Investigational	FLNC	2318	downregulated	Cytarabine results in decreased expression of FLNC mRNA	7q32.1	A21886
Cytarabine	Approved Investigational	FLRT2	23768	downregulated	Cytarabine results in decreased expression of FLRT2 mRNA	14q31.3	A21886
Cytarabine	Approved Investigational	FMO1	2326	downregulated	Cytarabine results in decreased expression of FMO1 mRNA	1q24.3	A21886
Cytarabine	Approved Investigational	FMO4	2329	downregulated	Cytarabine results in decreased expression of FMO4 mRNA	1q24.3	A21886
Cytarabine	Approved Investigational	FRZB	2487	downregulated	Cytarabine results in decreased expression of FRZB mRNA	2q32.1	A21886
Cytarabine	Approved Investigational	FSIP1	161835	upregulated	Cytarabine results in increased expression of FSIP1 mRNA	15q14	A21886
Cytarabine	Approved Investigational	FYN	2534	upregulated	Cytarabine results in increased expression of FYN mRNA	6q21	A21886
Cytarabine	Approved Investigational	GABARAPL1	23710	downregulated	Cytarabine results in decreased expression of GABARAPL1 mRNA	12p13.2	A21886
Cytarabine	Approved Investigational	GABARAPL3	23766	upregulated	Cytarabine results in increased expression of GABARAPL3 mRNA	15q26.1	A20985
Cytarabine	Approved Investigational	GABRP	2568	upregulated	Cytarabine results in increased expression of GABRP mRNA	5q35.1	A21886

Displaying entries 28401 - 28425 of 102031 in total

Pharmaco-transcriptomicsUp/down regulation of genes due to the metabolism of pharmaceutical compounds

Advanced Filter

Filter by Group

Filter by Market Availability